Kaken Pharmaceutical Co., Ltd. (TYO:4521)
Japan
· Delayed Price · Currency is JPY 4,285.00
+20.00 (0.47%)
At close: Mar 6, 2026
Kaken Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Revenue | 75,662 | 94,035 | 72,044 | 72,984 | 76,034 | 74,979 | Upgrade
|
| Revenue Growth (YoY) | -18.95% | 30.52% | -1.29% | -4.01% | 1.41% | -15.97% | Upgrade
|
| Cost of Revenue | 35,490 | 35,502 | 33,505 | 33,428 | 34,458 | 34,073 | Upgrade
|
| Gross Profit | 40,172 | 58,533 | 38,539 | 39,556 | 41,576 | 40,906 | Upgrade
|
| Selling, General & Admin | 19,919 | 18,501 | 16,165 | 15,476 | 15,833 | 16,155 | Upgrade
|
| Research & Development | 23,813 | 18,725 | 12,543 | 15,789 | 8,420 | 6,736 | Upgrade
|
| Operating Expenses | 44,003 | 37,497 | 29,025 | 31,556 | 24,511 | 23,118 | Upgrade
|
| Operating Income | -3,831 | 21,036 | 9,514 | 8,000 | 17,065 | 17,788 | Upgrade
|
| Interest Expense | -41 | -28 | -17 | -17 | -17 | -17 | Upgrade
|
| Interest & Investment Income | 803 | 613 | 479 | 438 | 396 | 393 | Upgrade
|
| Currency Exchange Gain (Loss) | -550 | -370 | -59 | - | -31 | -12 | Upgrade
|
| Other Non Operating Income (Expenses) | 2 | 28 | 32 | 306 | 129 | 69 | Upgrade
|
| EBT Excluding Unusual Items | -3,617 | 21,279 | 9,949 | 8,727 | 17,542 | 18,221 | Upgrade
|
| Gain (Loss) on Sale of Investments | 562 | -287 | 13 | 1 | 1 | 115 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 1 | 195 | 379 | Upgrade
|
| Asset Writedown | -1,569 | -1,556 | -167 | -1,911 | -3,091 | -54 | Upgrade
|
| Other Unusual Items | 22 | -1 | - | -1 | -762 | -4 | Upgrade
|
| Pretax Income | -4,602 | 19,435 | 9,795 | 6,817 | 13,885 | 18,657 | Upgrade
|
| Income Tax Expense | -770 | 5,490 | 1,770 | 1,377 | 4,336 | 5,252 | Upgrade
|
| Net Income | -3,832 | 13,945 | 8,025 | 5,440 | 9,549 | 13,405 | Upgrade
|
| Net Income to Common | -3,832 | 13,945 | 8,025 | 5,440 | 9,549 | 13,405 | Upgrade
|
| Net Income Growth | - | 73.77% | 47.52% | -43.03% | -28.77% | -30.80% | Upgrade
|
| Shares Outstanding (Basic) | 38 | 38 | 38 | 38 | 38 | 39 | Upgrade
|
| Shares Outstanding (Diluted) | 38 | 38 | 38 | 38 | 38 | 39 | Upgrade
|
| Shares Change (YoY) | -0.01% | 1.13% | 0.44% | -1.07% | -1.59% | -1.41% | Upgrade
|
| EPS (Basic) | -100.31 | 365.42 | 212.66 | 144.79 | 251.44 | 347.37 | Upgrade
|
| EPS (Diluted) | -100.31 | 365.42 | 212.66 | 144.79 | 251.44 | 347.37 | Upgrade
|
| EPS Growth | - | 71.83% | 46.87% | -42.41% | -27.62% | -29.81% | Upgrade
|
| Free Cash Flow | - | 25,642 | 716 | 7,266 | 10,350 | 12,407 | Upgrade
|
| Free Cash Flow Per Share | - | 671.92 | 18.97 | 193.39 | 272.53 | 321.51 | Upgrade
|
| Dividend Per Share | 170.000 | 150.000 | 150.000 | 150.000 | 150.000 | 150.000 | Upgrade
|
| Dividend Growth | 13.33% | - | - | - | - | - | Upgrade
|
| Gross Margin | - | 62.25% | 53.49% | 54.20% | 54.68% | 54.56% | Upgrade
|
| Operating Margin | -5.06% | 22.37% | 13.21% | 10.96% | 22.44% | 23.72% | Upgrade
|
| Profit Margin | -5.07% | 14.83% | 11.14% | 7.45% | 12.56% | 17.88% | Upgrade
|
| Free Cash Flow Margin | - | 27.27% | 0.99% | 9.96% | 13.61% | 16.55% | Upgrade
|
| EBITDA | -1,426 | 23,590 | 12,267 | 10,568 | 19,551 | 20,106 | Upgrade
|
| EBITDA Margin | - | 25.09% | 17.03% | 14.48% | 25.71% | 26.82% | Upgrade
|
| D&A For EBITDA | 2,405 | 2,554 | 2,753 | 2,568 | 2,486 | 2,318 | Upgrade
|
| EBIT | -3,831 | 21,036 | 9,514 | 8,000 | 17,065 | 17,788 | Upgrade
|
| EBIT Margin | - | 22.37% | 13.21% | 10.96% | 22.44% | 23.72% | Upgrade
|
| Effective Tax Rate | - | 28.25% | 18.07% | 20.20% | 31.23% | 28.15% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.